| 20.05 11:14 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
| 20.05 11:14 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
| 20.05 08:44 | Astrazeneca plant 1,5 Mrd USD teure Produktionsanlage in Singapur |
| 20.05 08:21 | dpa-AFX: AstraZeneca To Build $1.5 Bln Manufacturing Facility In Singapore For Antibody Drug Conjugates |
| 20.05 08:05 | dpa-AFX: *ASTRAZENECA PLANS $1.5 BLN MANUFACTURING FACILITY FOR ANTIBODY DRUG CONJUGATES IN SINGAPORE |
| 20.05 08:04 | dpa-AFX: *ASTRAZENECA TO START BUILDING ADCS FACILITY IN SINGAPORE BY 2024, OPERATIONAL BY 2029 |
| 20.05 08:02 | dpa-AFX: *ASTRAZENECA INTENDS TO BUILD $1.5 BLN MANUFACTURING FACILITY IN SINGAPORE FOR ANTIBODY DRUG CONJUGATES |
| 20.05 03:38 | dpa-AFX: AstraZeneca: New Data Shows Tezspire's Role In Future COPD Treatment |
| 16.05 09:18 | dpa-AFX: AZN:Phase III Trial Of Sipavibart Met Main Goal In Preventing COVID-19 In Immunocompromised Patients |
| 16.05 08:27 | dpa-AFX: *ASTRAZENECA SAYS SUPERNOVA PHASE III TRIAL OF SIPAVIBART MEETS PRIMARY ENDPOINTS IN PREVENTING COVID-19 |
| 16.05 08:18 | dpa-AFX: *AZN : PHASE III TRIAL OF SIPAVIBART ANTIBODY MEETS MAIN GOAL IN PREVENTING COVID-19 IN IMMUNOCOMPROMISED PATIENT |
| 15.05 09:18 | dpa-AFX: ANALYSE-FLASH: UBS belässt Astrazeneca auf 'Sell' - Ziel 10500 Pence |
| 15.05 09:18 | dpa-AFX: UBS belässt Astrazeneca auf 'Sell' - Ziel 10500 Pence |
| 14.05 13:17 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
| 14.05 13:17 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
| 13.05 13:42 | dpa-AFX: Microsoft will vier Milliarden Euro in Frankreich investieren |
| 13.05 13:42 | Microsoft will vier Milliarden Euro in Frankreich investieren |
| 13.05 13:37 | dpa-AFX: Microsoft will vier Milliarden Euro in Frankreich investieren |
| 13.05 11:20 | dpa-AFX: Amazon, Microsoft, Pfizer To Invest Billions In French Projects |
| 09.05 07:10 | dpa-AFX: HINTERGRUND: Zulassungsaus für Corona-Impfstoff 'Vaxzevria' - Ungewöhnlich? |
|
|
